GlassScriptPrepare for your visit
Peter C Hanley
Cardiovascular Disease · Fort Wayne, IN · NPI 1346220993
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$3,873.66
in general payments reported to CMS, 2019-2025 · $501 in 2025
The $501 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Who reported paying
General payments only, top 6 by amount.
- Amgen INC. $1,198.55
- Esperion Therapeutics, INC. $590.12
- Novartis Pharmaceuticals Corporation $425.65
- Regeneron Healthcare Solutions, INC. $242.62
- Astrazeneca Pharmaceuticals LP $174.53
- Boehringer Ingelheim Pharmaceuticals, INC. $174.19
Drugs and devices associated with these payments
Repatha Leqvio Evkeeza Verquvo Cardiomems Tryngolza Entresto Vyndaqel Lifevest Jardiance Nexletol Attruby
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Peter Hanley listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/241859/peter-c-hanley